| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 10/04/2001 | CA2404172A1 Antiprogestins with partial agonist activity |
| 10/04/2001 | CA2403800A1 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 10/04/2001 | CA2403557A1 Crystalline form vii of cabergoline |
| 10/04/2001 | CA2402735A1 Human transcription factors |
| 10/04/2001 | CA2402613A1 Cationic liposomes |
| 10/04/2001 | CA2402187A1 Intracorporeal medicaments comprising halogenated xanthene for photodynamic treatment of disease |
| 10/04/2001 | CA2399540A1 Crystalline form ii of cabergoline |
| 10/04/2001 | CA2374911A1 G-protein coupled receptors |
| 10/03/2001 | CN1315936A Compounds and compositions for delivering active agents |
| 10/03/2001 | CN1315860A Method for treating hot flashes in humans |
| 10/02/2001 | US6297380 Process and intermediates for growth hormone secretagogues |
| 10/02/2001 | US6297379 Thienopyrimidine compounds, their production and use |
| 09/27/2001 | WO2001071005A2 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 09/27/2001 | WO2001071004A2 Proteases |
| 09/27/2001 | WO2001070969A2 Regulation of human latrophilin-like g protein-coupled receptor |
| 09/27/2001 | WO2001070807A2 G-protein associated molecules |
| 09/27/2001 | WO2001070754A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 09/27/2001 | WO2001070753A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 09/27/2001 | WO2001070729A1 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors |
| 09/27/2001 | WO2001070695A1 Pyridine derivatives as inhibitors of p38 |
| 09/27/2001 | WO2001070694A1 Amorphous torasemide modification |
| 09/27/2001 | WO2001070663A2 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 09/27/2001 | WO2001070662A2 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors |
| 09/27/2001 | WO2001070228A1 Antagonists of gonadotropin releasing hormone |
| 09/27/2001 | WO2001070227A1 Antagonists of gonadotropin releasing hormone |
| 09/27/2001 | WO2001070219A1 Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
| 09/27/2001 | WO2001019829A3 Pyrazolopyrimidines as therapeutic agents |
| 09/27/2001 | WO2001012606B1 Tetrahydroquinoline derivatives having retinoid-like biological activity |
| 09/27/2001 | WO2000012047A3 Enhancement of return to independent living status with a growth hormone secretagogue |
| 09/27/2001 | US20010025051 Administering to a breast cancer patient an effective amount of hydroxy containing bicyclic aromatic or heteroaromatic derivatives |
| 09/27/2001 | US20010025042 A fused nitrogen containing heterocyclic compound useful for treating psychiatric and neurological disorders, anxiety, post-traumatic stress, supranuclear palsy, feeding, immunological, cardiovascular and hypersensitivity disorders |
| 09/27/2001 | US20010025036 Modifying the structure of a 1alpha-hydroxylated vitamin D compound to increase its in vivo activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents 1alphahydroxy in axial orientation |
| 09/27/2001 | US20010024658 A delayed release pharmaceutical dosage form for oral administration of heparin comprising a low molecular weight heparin, a bile salt or acid, and a surfactant selected from hydrophilc and lipophilic, and a means for sustained release |
| 09/27/2001 | CA2406993A1 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 09/27/2001 | CA2403828A1 Inhibitors of p38 |
| 09/27/2001 | CA2403553A1 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 09/27/2001 | CA2402763A1 Proteases |
| 09/27/2001 | CA2402747A1 G-protein associated molecules |
| 09/27/2001 | CA2402414A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 09/27/2001 | CA2401984A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 09/27/2001 | CA2401908A1 Amorphous torasemide modification |
| 09/26/2001 | EP1136482A1 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
| 09/26/2001 | EP1135498A1 Antibody variants with higher binding affinity compared to parent antibodies |
| 09/26/2001 | EP1135489A1 Pth1r and pth3r receptors |
| 09/26/2001 | EP1135484A2 Gtpase associated proteins |
| 09/26/2001 | EP1135403A1 17beta-acyl-17alpha-propynyl-11beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 09/26/2001 | EP1135154A1 Improvement of folliculogenesis |
| 09/26/2001 | EP1135127A1 New pharmaceutical composition and the process for its preparation |
| 09/26/2001 | EP1135123A1 Use of isatin derivatives as ion channel activating agents |
| 09/26/2001 | EP1135115A2 Use of sibutramine for the treatment of disorders of the central nervous system secondary to organic impairments |
| 09/26/2001 | CN1314912A Tartrate salt of a sabstituted dipentide as growth hormone secretagogue |
| 09/26/2001 | CN1314347A Six kinds of isoquinoline alkaloid |
| 09/25/2001 | US6294531 Calcilytic compounds |
| 09/25/2001 | US6294522 Compounds for treatment of cardiovascular disorders |
| 09/25/2001 | US6294177 Particularly useful in the treatment of mastitis. |
| 09/20/2001 | WO2001068888A2 Production of chimeric capsid vectors |
| 09/20/2001 | WO2001068855A2 Gtp-binding protein gamma-12 subunit |
| 09/20/2001 | WO2001068828A2 Compositions and methods for regulated protein expression in gut |
| 09/20/2001 | WO2001068697A2 Methods and compositions for immunoregulation |
| 09/20/2001 | WO2001068676A2 Lhrh-antagonists, production and use thereof as medicament |
| 09/20/2001 | WO2001068670A2 Family of mechanically sensitive human potassium channels activated by polyunsaturated fatty acids and use thereof |
| 09/20/2001 | WO2001068669A1 6-oxygenated steroidal estrogens with aromatic a and b rings |
| 09/20/2001 | WO2001068634A1 4-fluoroalkyl-2h-benzopyrans with anti-estrogenic activity |
| 09/20/2001 | WO2001068619A1 5-amide substituted diarylamines as mex inhibitors |
| 09/20/2001 | WO2001068582A1 Novel fatty acid analogous |
| 09/20/2001 | WO2001068075A2 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals |
| 09/20/2001 | WO2001068068A2 Compounds capable of binding with the cytoskeleton |
| 09/20/2001 | WO2001068058A1 Multilayer pharmaceutical product for release in the colon |
| 09/20/2001 | WO2001029070A8 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 09/20/2001 | WO2001018025A3 17alpha propynyl 11-aryl steroids |
| 09/20/2001 | WO2000009537A3 Compounds having growth hormone releasing activity |
| 09/20/2001 | US20010023243 Method for treating parathyroid disorders |
| 09/20/2001 | US20010022970 Halogenated xanthan compound |
| 09/20/2001 | DE10013029A1 Multilayer formulation for controlled drug release in colon, comprising drug-containing core having inner and outer coatings of acrylic copolymers with quaternary ammonium and anionic groups respectively |
| 09/20/2001 | CA2403420A1 Compounds capable of binding with the cytoskeleton |
| 09/20/2001 | CA2403393A1 Methods and compositions for immunoregulation |
| 09/20/2001 | CA2403205A1 Compositions and methods of regulated protein expression in gut endocrine k cells |
| 09/20/2001 | CA2403201A1 Family of mechanically sensitive human potassium channels activated by polyunsaturated fatty acids and use thereof |
| 09/20/2001 | CA2403017A1 5-amide substituted diarylamines as mex inhibitors |
| 09/20/2001 | CA2373110A1 Production of chimeric capsid vectors |
| 09/19/2001 | EP1133522A1 Antagonistic analogs of gh-rh inhibiting igf-i and -ii |
| 09/19/2001 | EP1133494A1 8-azabicyclo 3.2.1]oct-2-ene and -octane derivatives |
| 09/19/2001 | EP1133488A1 Propanoic acid derivatives as integrin inhibitors |
| 09/19/2001 | EP1133280A1 Method of preparing stable suspensions of insoluble microparticles |
| 09/19/2001 | EP0889901B1 Process and intermediates for the synthesis of lhrh antagonists |
| 09/19/2001 | CN1313862A Novel 17-halogenated 19-Nor steroids, method and intermediates for preparing same, use as medicines and pharmaceutical compositions containing same |
| 09/19/2001 | CN1313853A Oxindole derivatives as growth hormone releasers |
| 09/19/2001 | CN1313280A Benzheterocyclic derivatives |
| 09/19/2001 | CN1313107A Chinese medicine for prepventing and treating iatrogenic hypercortisonism |
| 09/18/2001 | US6291505 Pyrazole estrogen receptor agonist and antagonist |
| 09/18/2001 | US6291484 Treatment of the various medical conditions associated with postmenopausal syndrome |
| 09/18/2001 | US6291458 Morpholinobenzamide salts |
| 09/18/2001 | US6291451 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| 09/18/2001 | US6291195 Generating ligands which bind preferential human receptors; incubate cells expressing preferential binding protein with modulator, detect adjustment in binding activity |
| 09/18/2001 | US6290930 Cosolvent, especially ethanol, present in an amount that dissolves or solubilizes the budesonide in the mixture of cosolvent and propellant. |
| 09/18/2001 | CA2046050C Bis[4-(2,6-di-alkyl)phenol]silane derivatives as antiatherosclerotic agents |
| 09/13/2001 | WO2001066706A1 Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | WO2001066595A2 Human fgf-23 gene and gene expression products |
| 09/13/2001 | WO2001066159A1 Novel natural polymer-based material with improved properties for use in human and veterinary medicine and the method of manufacturing such |
| 09/13/2001 | WO2001066134A1 Rfrp-containing prolactin secretion regulatory agent |